Limitations, agreements, and source contact

A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers · Source last updated 2025-09-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

point Of Contact

email

ClinicalTrialDisclosure@JazzPharma.com

organization

Jazz Pharmaceuticals Inc.

phone

215-832-3750

title

Clinical Trial Disclosure & Transparency

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice